August 27, 2025
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue...
Read more